➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Johnson and Johnson
Dow
Moodys
Merck

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 9,814,782

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,814,782
Title:Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
Abstract: The present invention relates to an antibody in which a motif composed of an amino acid or peptide sequence including one or more cysteine residues is bound to the terminus of a parent antibody, particularly the terminus of the heavy chain of the parent antibody. Also, the present invention relates to a modified antibody-drug conjugate (mADC) comprising a drug bound to the antibody, and a method for producing the antibody or the modified antibody-drug conjugate. The modified antibody-drug conjugate according to the invention can accurately deliver the drug to a target cell due its high specificity to antigen, and thus can increase the therapeutic effect of the drug. Also, it can increase the usability of drugs, particularly anticancer drugs, the use of which is restricted due to their toxicity, despite their high efficacy. Moreover, the invention relates to a composition for treatment of diseases, particularly cancers, which comprise the modified antibody-drug conjugate.
Inventor(s): Park; Soon Jae (Daejeon, KR), Chung; Hye-Shin (Daejeon, KR), Kwon; Seonhun (Seoul, KR), Lee; Sunbae (Daejeon, KR), Yoo; Sun-ah (Daejeon, KR), Kim; Yong Mo (Jeoneup-si, KR)
Assignee: ALTEOGEN INC. (Daejeon, KR)
Application Number:14/380,068
Patent Claims:see list of patent claims

Details for Patent 9,814,782

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial ALTEOGEN INC. (Daejeon, KR) 2032-02-24 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial ALTEOGEN INC. (Daejeon, KR) 2032-02-24 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial ALTEOGEN INC. (Daejeon, KR) 2032-02-24 RX Orphan search
Bristol Myers Squibb YERVOY ipilimumab INJECTABLE; INJECTION 125377 001 2011-03-25   Start Trial ALTEOGEN INC. (Daejeon, KR) 2032-02-24 RX Orphan search
Novartis ARZERRA ofatumumab INJECTABLE; INJECTION 125326 001 2009-10-26   Start Trial ALTEOGEN INC. (Daejeon, KR) 2032-02-24 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial ALTEOGEN INC. (Daejeon, KR) 2032-02-24 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial ALTEOGEN INC. (Daejeon, KR) 2032-02-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,814,782

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Colorcon
Johnson and Johnson
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.